NASDAQ:FNCH Finch Therapeutics Group (FNCH) Stock Price, News & Analysis $12.05 +0.60 (+5.24%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About Finch Therapeutics Group Stock (NASDAQ:FNCH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get FNCH alerts:Sign Up Key Stats Today's Range$11.40▼$12.0550-Day Range$11.00▼$12.1552-Week Range$0.80▼$14.26Volume4,460 shsAverage Volume3,659 shsMarket Capitalization$19.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Read More… Ever heard of this 8-day bitcoin profit window? (Ad)Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. Receive FNCH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter. Email Address FNCH Stock News HeadlinesFinch Therapeutics Group, Inc.: Finch Announces Delisting from Nasdaq and SEC DeregistrationOctober 23, 2024 | finanznachrichten.deFinch Therapeutics announces Nasdaq delisting, SEC deregistrationOctober 22, 2024 | markets.businessinsider.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 24, 2024 | DTI (Ad)Finch Therapeutics Group to Delist from NasdaqOctober 22, 2024 | markets.businessinsider.comFinch Announces Delisting from Nasdaq and SEC DeregistrationOctober 21, 2024 | globenewswire.comFinch Therapeutics Gr (OTC:FNCH) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comFinch wins US jury trial against Ferring over fecal-transplant patentsAugust 10, 2024 | reuters.comFinch Therapeutics Group (NASDAQ: FNCH)April 14, 2024 | fool.comSee More Headlines FNCH Stock Analysis - Frequently Asked Questions How have FNCH shares performed this year? Finch Therapeutics Group's stock was trading at $3.61 at the beginning of the year. Since then, FNCH shares have increased by 233.8% and is now trading at $12.05. View the best growth stocks for 2024 here. How were Finch Therapeutics Group's earnings last quarter? Finch Therapeutics Group, Inc. (NASDAQ:FNCH) issued its earnings results on Wednesday, November, 10th. The company reported ($6.30) EPS for the quarter, topping the consensus estimate of ($12.60) by $6.30. The firm earned $11.34 million during the quarter. When did Finch Therapeutics Group's stock split? Finch Therapeutics Group shares reverse split before market open on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Finch Therapeutics Group IPO? Finch Therapeutics Group (FNCH) raised $101 million in an IPO on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Finch Therapeutics Group? Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Finch Therapeutics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Finch Therapeutics Group investors own include CNS Pharmaceuticals (CNSP), Faraday Future Intelligent Electric (FFIE), Allarity Therapeutics (ALLR), Aridis Pharmaceuticals (ARDS), Meta Platforms (META), NVIDIA (NVDA) and Altamira Therapeutics (CYTO). Company Calendar Last Earnings11/10/2021Today11/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FNCH CUSIPN/A CIK1733257 Webwww.finchtherapeutics.com Phone617-229-6499FaxN/AEmployees190Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.14% Return on Assets-26.92% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual Sales$110,000.00 Price / Sales175.93 Cash FlowN/A Price / Cash FlowN/A Book Value$14.25 per share Price / Book0.85Miscellaneous Outstanding Shares1,606,000Free Float885,000Market Cap$19.35 million OptionableNo Data Beta1.34 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:FNCH) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.